CA3016341A1 - Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections - Google Patents
Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections Download PDFInfo
- Publication number
- CA3016341A1 CA3016341A1 CA3016341A CA3016341A CA3016341A1 CA 3016341 A1 CA3016341 A1 CA 3016341A1 CA 3016341 A CA3016341 A CA 3016341A CA 3016341 A CA3016341 A CA 3016341A CA 3016341 A1 CA3016341 A1 CA 3016341A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- optionally substituted
- heta
- compound
- arya
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304447P | 2016-03-07 | 2016-03-07 | |
| US62/304,447 | 2016-03-07 | ||
| PCT/US2017/020303 WO2017155765A1 (en) | 2016-03-07 | 2017-03-02 | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3016341A1 true CA3016341A1 (en) | 2017-09-14 |
Family
ID=59789685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3016341A Pending CA3016341A1 (en) | 2016-03-07 | 2017-03-02 | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10407421B2 (enExample) |
| EP (1) | EP3426248B1 (enExample) |
| JP (1) | JP7034929B2 (enExample) |
| KR (1) | KR102408800B1 (enExample) |
| CN (1) | CN108778273B (enExample) |
| AU (1) | AU2017228870B2 (enExample) |
| BR (1) | BR112018067930B1 (enExample) |
| CA (1) | CA3016341A1 (enExample) |
| MA (1) | MA43811A (enExample) |
| MX (1) | MX2018010878A (enExample) |
| RU (1) | RU2733402C2 (enExample) |
| WO (1) | WO2017155765A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111303144A (zh) * | 2019-12-13 | 2020-06-19 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10407421B2 (en) | 2016-03-07 | 2019-09-10 | Merck Sharp & Dohme Corp | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| MX2019010302A (es) | 2017-03-30 | 2019-11-21 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1. |
| GEAP202215303A (en) * | 2017-10-02 | 2022-04-11 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| EP3747883A4 (en) * | 2018-01-29 | 2020-12-16 | Medshine Discovery Inc. | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION |
| JP7386841B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| TW202023558A (zh) | 2018-10-03 | 2020-07-01 | 美商建南德克公司 | 8-胺基異喹啉化合物及其用途 |
| US20220002288A1 (en) * | 2018-11-13 | 2022-01-06 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Monobactam compounds and use therefor |
| WO2020125670A1 (zh) * | 2018-12-18 | 2020-06-25 | 南京明德新药研发有限公司 | 单环β-内酰胺化合物在制药中的应用 |
| CN110963967B (zh) * | 2019-11-25 | 2021-02-12 | 武汉智顿科技发展有限公司 | 一种2-甲基-4-氨基喹啉的制备方法 |
| CN111018777B (zh) * | 2019-11-25 | 2021-02-12 | 武汉智顿科技发展有限公司 | 一种地喹氯铵的制备方法 |
| US12491180B2 (en) | 2019-12-19 | 2025-12-09 | Shenzhen Optimum Biological Technology Co., Ltd | Application of compound in treating pneumonia |
| WO2022047603A1 (en) | 2020-09-01 | 2022-03-10 | Ningxia Academy Of Agriculture And Forestry Sciences | Beta-lactamase inhibitors and their preparation |
| US11780832B2 (en) | 2021-03-31 | 2023-10-10 | Fedora Pharmaceuticals Inc. | Lactivicin compounds, their preparation and use as antibacterial agents |
| US12410166B2 (en) | 2021-05-07 | 2025-09-09 | Ningxia Academy Of Agriculture And Forestry Sciences | Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors |
| US20240390335A1 (en) * | 2021-11-09 | 2024-11-28 | Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences | Pharmaceutical composition containing beta-lactam compound and use thereof |
| KR20250093507A (ko) * | 2022-11-07 | 2025-06-24 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 퀴나졸린 유도체 |
| CN121955228A (zh) * | 2025-12-31 | 2026-05-01 | 北京大学人民医院 | 同时检测亚胺培南、雷利巴坦和西司他丁的方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684722A (en) | 1986-01-06 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Monosulfactams |
| US5250691A (en) * | 1991-09-09 | 1993-10-05 | E. R. Squibb & Sons, Inc. | Heteroaryl derivatives of monocyclic beta-lactam antibiotics |
| MY127641A (en) | 1995-10-12 | 2006-12-29 | Essential Therapeutics Inc | Cephalosporin antibiotics |
| RU2269525C2 (ru) * | 2000-08-10 | 2006-02-10 | Бритиш Биотех Фармасьютикалс Лимитед | Антибактериальные агенты |
| KR101403164B1 (ko) | 2005-12-07 | 2014-06-03 | 바실리어 파마슈티카 아게 | 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합 |
| CA2691987C (en) | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| JP5777725B2 (ja) | 2010-11-29 | 2015-09-09 | ファイザー・インク | モノバクタム |
| UY34585A (es) | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| US20140275007A1 (en) | 2013-03-14 | 2014-09-18 | Rempex Pharmaceuticals, Inc. | Oxamazin antibiotics |
| HUE042134T2 (hu) | 2014-03-24 | 2019-06-28 | Novartis Ag | Monobaktám szerves vegyületek bakteriális fertõzések kezelésére |
| US10407421B2 (en) | 2016-03-07 | 2019-09-10 | Merck Sharp & Dohme Corp | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
-
2017
- 2017-03-02 US US16/076,781 patent/US10407421B2/en active Active
- 2017-03-02 RU RU2018134948A patent/RU2733402C2/ru active
- 2017-03-02 WO PCT/US2017/020303 patent/WO2017155765A1/en not_active Ceased
- 2017-03-02 JP JP2018546678A patent/JP7034929B2/ja active Active
- 2017-03-02 EP EP17763763.4A patent/EP3426248B1/en active Active
- 2017-03-02 CN CN201780015430.2A patent/CN108778273B/zh active Active
- 2017-03-02 MX MX2018010878A patent/MX2018010878A/es unknown
- 2017-03-02 BR BR112018067930-5A patent/BR112018067930B1/pt active IP Right Grant
- 2017-03-02 AU AU2017228870A patent/AU2017228870B2/en active Active
- 2017-03-02 KR KR1020187028417A patent/KR102408800B1/ko active Active
- 2017-03-02 CA CA3016341A patent/CA3016341A1/en active Pending
- 2017-03-02 MA MA043811A patent/MA43811A/fr unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111303144A (zh) * | 2019-12-13 | 2020-06-19 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
| CN111303144B (zh) * | 2019-12-13 | 2020-11-27 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018010878A (es) | 2018-11-09 |
| CN108778273B (zh) | 2022-06-17 |
| WO2017155765A1 (en) | 2017-09-14 |
| KR20180121948A (ko) | 2018-11-09 |
| US10407421B2 (en) | 2019-09-10 |
| JP2019507768A (ja) | 2019-03-22 |
| MA43811A (fr) | 2018-11-28 |
| EP3426248A1 (en) | 2019-01-16 |
| RU2018134948A (ru) | 2020-04-08 |
| RU2733402C2 (ru) | 2020-10-01 |
| BR112018067930A2 (pt) | 2019-01-22 |
| EP3426248A4 (en) | 2019-07-10 |
| RU2018134948A3 (enExample) | 2020-04-08 |
| US20190071436A1 (en) | 2019-03-07 |
| JP7034929B2 (ja) | 2022-03-14 |
| AU2017228870B2 (en) | 2021-02-18 |
| BR112018067930A8 (pt) | 2023-04-11 |
| KR102408800B1 (ko) | 2022-06-13 |
| BR112018067930B1 (pt) | 2024-02-15 |
| EP3426248B1 (en) | 2023-11-15 |
| CN108778273A (zh) | 2018-11-09 |
| AU2017228870A1 (en) | 2018-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017228870B2 (en) | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | |
| CA3008006C (en) | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | |
| CA3076022C (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| CA2990234A1 (en) | 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | |
| JP7078807B2 (ja) | 大環状広域スペクトル抗生物質 | |
| WO2016018702A1 (en) | FACTOR XIa INHIBITORS | |
| BR112020006381B1 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BR112018010962B1 (pt) | Composto, sal de ácido trifluoroacético, composição farmacêutica, e, uso de um composto | |
| HK40029711A (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| HK40029711B (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| EA044287B1 (ru) | Хроманмонобактамовые соединения для лечения бактериальных инфекций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211213 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241010 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241106 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241119 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241126 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241126 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241126 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241126 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250704 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250704 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251216 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251216 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260309 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260413 |